← back to search

Jitesh Chauhan

King's College London · GB
Area of research
Radiology, Nuclear Medicine and Imaging · Immunology
Research interest
Research interests include Monoclonal and Polyclonal Antibodies Research, Mast cells and histamine, Immunotherapy and Immune Responses, and HER2/EGFR in Cancer Research.
h-index
13
citations
786
works
64
NIH funding
primary concept
email

Recent publications

Hyperinflammatory repolarisation of ovarian cancer patient macrophages by anti-tumour IgE antibody, MOv18, restricts an immunosuppressive macrophage:Treg cell interaction
Nature Communications 2025cited by 13position: middledoi
Basophil Activation Test: Bridging Allergy and Oncology for Diagnostic, Therapeutic and Prognostic Applications in <scp>AllergoOncology</scp> : An <scp>EAACI</scp> Position Paper
Allergy 2025cited by 10position: middledoi
Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma
Cancers 2024cited by 13position: middledoi
Granulocytes and mast cells in AllergoOncology—Bridging allergy to cancer: An <scp>EAACI</scp> position paper
Allergy 2024cited by 10position: middledoi
Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4
Nature Communications 2023cited by 40position: firstdoi
B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma
Nature Communications 2023cited by 38position: middledoi
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial
Nature Communications 2023cited by 35position: middledoi
Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes
British Journal of Cancer 2022cited by 79position: middledoi
Clinical and Translational Significance of Basophils in Patients with Cancer
Cells 2022cited by 41position: firstdoi
Enriched circulating and tumor-resident TGF-β <sup>+</sup> regulatory B cells in patients with melanoma promote FOXP3 <sup>+</sup> Tregs
OncoImmunology 2022cited by 38position: middledoi
Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
European Journal of Immunology 2021cited by 195position: middledoi
B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies
Frontiers in Immunology 2021cited by 68position: middledoi
Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments
Cancers 2021cited by 39position: middledoi
Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical Outcome
Cells 2020cited by 47position: middledoi
IgE Antibodies against Cancer: Efficacy and Safety
Antibodies 2020cited by 38position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Sophia N. Karagiannis · Guy's Hospital10 papers (2020–2025)Heather J. Bax · King's College London9 papers (2020–2025)James Spicer · King's College London7 papers (2020–2022)Debra H. Josephs · Guy's Hospital5 papers (2020–2022)Mano Nakamura · Guy's Hospital4 papers (2020–2021)Katie E. Lacy · King's College London4 papers (2021–2022)Chara Stavraka · King's College London4 papers (2020–2022)Silvia Crescioli · King's College London4 papers (2021–2022)Gabriel Osborn · Guy's Hospital4 papers (2020–2021)Jenny L. C. Geh · St Thomas' Hospital4 papers (2021–2024)Anthony Cheung · King's College London3 papers (2021–2022)Sophia Tsoka · King's College London3 papers (2021–2022)Roman Laddach · Guy's Hospital3 papers (2021–2022)Zena Willsmore · King's College London3 papers (2021–2022)R. J. C. Harris · Adaptimmune (United Kingdom)3 papers (2021–2022)Ciaran Healy · St Thomas' Hospital3 papers (2021–2022)Alicia M. Chenoweth · Guy's Hospital3 papers (2021–2021)Alastair D. MacKenzie Ross · St Thomas' Hospital3 papers (2021–2022)Francesca Levi‐Schaffer · Hong Kong Baptist University2 papers (2024–2025)Uta Jappe · Johannes Gutenberg University Mainz2 papers (2024–2025)